[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol; 2009 Jul;45(7):574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity of cetuximab in terms of clinical benefit rate (CBR) defined as the occurrence of objective response (CR or PR) or stable disease (SD) for >or=6months was investigated.
  • From April to December 2005, 30 patients [23 adenoid cystic carcinoma (ACC) and 7 non-ACC] were treated with cetuximab at 400mg/m(2)/week followed by 250mg/m(2)/week until progression, major toxicity or voluntary discontinuation.
  • Skin toxicity was the main adverse event.
  • Skin rash >or=G2, EGFR overexpression and EGFR copy number were not statistically correlated to CB.
  • In RMSGCs further evaluations of EGFR targeting agents are advisable and should take place by appropriate tumor biological selection, differentiating ACC from non-ACC.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804410.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


2. Funk JO: [Aspirin against cylindromatosis? Molecular functions of the CYLD tumor suppressor]. Hautarzt; 2004 Mar;55(3):327-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Carcinoma, Adenoid Cystic / genetics. Genes, Tumor Suppressor. Head and Neck Neoplasms / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / genetics. DNA Mutational Analysis. Humans. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15029443.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / CYLD protein, human; 0 / NF-kappa B; 0 / Tumor Suppressor Proteins; R16CO5Y76E / Aspirin
  •  go-up   go-down


3. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is an increased incidence of second malignant neoplasms in survivors of childhood cancers.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • These patients were initially treated for a variety of childhood cancers with a combination of radiation and chemotherapy.
  • The pathology of the salivary gland tumors were mucoepidermoid carcinoma (10), adenoid cystic carcinoma (1) , and pleomorphic adenoma (1).
  • All patients were treated with surgical excision of the primary tumor, and postoperative radiation was added in select patients.
  • The majority of these neoplasms are malignant; mucoepidermoid carcinoma occurs most frequently.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


Advertisement
4. Massoumi R, Paus R: Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays; 2007 Dec;29(12):1203-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysing cylindromatosis and the associated defects in the CYLD gene is providing novel insights into the molecular principles of epithelial growth control and carcinogenesis in, and beyond, the skin.
  • In this review, we summarize the histopathology and histogenesis of cylindromas, and the available genetic information on patients with these skin appendage tumors.
  • Focusing on recent data concerning the normal functions and signaling interactions of the CYLD gene product, we explain how CYLD interferes with TNF-alpha or TLR-mediated signaling as well as with JNK or NF-kappaB-dependent p65/50 signaling to limit inflammation.
  • In addition, we delineate how CYLD interferes with activation of the proto-oncogene Bcl(3) and with cyclin D1 expression to limit tumorigenesis, and chart how tumor growth-promoting agents or UV light and inflammatory mediators can activate CYLD.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / pathology. Epithelium / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Animals. Humans. NF-kappa B / metabolism. Protein Binding. Ubiquitin / metabolism

  • Genetics Home Reference. consumer health - familial cylindromatosis.
  • Genetics Home Reference. consumer health - CYLD gene.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley Periodicals, Inc
  • (PMID = 18008375.001).
  • [ISSN] 0265-9247
  • [Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology
  • [ISO-abbreviation] Bioessays
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / NF-kappa B; 0 / Tumor Suppressor Proteins; 0 / Ubiquitin
  • [Number-of-references] 76
  •  go-up   go-down


5. Chaer RA, Lipnick S: Images in clinical medicine. Cylindroma. N Engl J Med; 2004 Dec 9;351(24):2530
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in clinical medicine. Cylindroma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Head and Neck Neoplasms / pathology. Scalp / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15590955.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Fresini A, Rossiello L, Severino BU, Del Prete M, Satriano RA: Giant basal cell carcinoma. Skinmed; 2007 Jul-Aug;6(4):204-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma.
  • A 72-year-old white man presented with a large cutaneous tumor on his back.
  • Perilesional skin appeared edematous, probably owing to inflammation and impaired lymphatic flow.
  • The patient's history revealed mild hypertension, ischemic cardiopathy treated with percutaneous transluminal coronary angioplasty and anticoagulant drugs, and moderate chronic renal insufficiency.
  • Histologic examination of a biopsy specimen taken from the margin of the lesion displayed a superficial area of ulceration and invasion of the deeper dermis and subcutaneous tissue (Figure 2A and Figure 2B).
  • The tumor mostly showed an adenoid pattern: gland-like structures and cystic spaces sometimes containing amorphous or granular material, surrounded by strands of basaloid cells devoid of any peripheral palisading (Figure 2C).
  • In some areas, the adenoid pattern coexisted with infiltrated areas characterized by thin and elongated strands or cords of basaloid cells with irregular and jagged peripheral contours within a fibrous or edematous stroma (Figure 2D).
  • Therefore, a diagnosis of basal cell carcinoma, adenoid subtype, was made.
  • Because the patient was taking anticoagulant drugs and had unstable renal and cardiac function, surgical treatment was at least temporarily excluded, and the patient was referred for radiation therapy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618177.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Wickström SA, Masoumi KC, Khochbin S, Fässler R, Massoumi R: CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J; 2010 Jan 6;29(1):131-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CYLD is a tumour-suppressor gene that is mutated in a benign skin tumour syndrome called cylindromatosis.
  • The CYLD gene product is a deubiquitinating enzyme that was shown to regulate cell proliferation, cell survival and inflammatory responses, mainly through inhibiting NF-kappaB signalling.
  • [MeSH-major] Cell Cycle / physiology. Histone Deacetylases / metabolism. Tubulin / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Acetylation. Animals. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Catalytic Domain. Cell Line, Tumor. Cytokinesis. Genes, Tumor Suppressor. Humans. Keratinocytes / cytology. Keratinocytes / drug effects. Keratinocytes / metabolism. Melanocytes / cytology. Melanocytes / drug effects. Melanocytes / metabolism. Melanoma / genetics. Melanoma / metabolism. Melanoma / pathology. Mice. Microtubules / metabolism. Mutation. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Skin Neoplasms / genetics. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Tetradecanoylphorbol Acetate / pharmacology


8. Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R, El-Naggar AK: ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol; 2005 Jul;41(6):580-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion!
  • To determine the association of this gene in tumorigenesis and perineural invasion, we analyzed the expression and functional status of ICAM-5 mRNA transcripts in 30 different human cancer cell lines and 25 head and neck squamous carcinoma specimens by reverse-transcriptase polymerase chain reaction (cell lines and specimens) and in vitro functional assays (cell lines).
  • ICAM-5 transcripts were detected in 28 (93%) of 30 cell lines derived from primary head and neck, colon, thyroid, cervical, pancreatic, skin, and adenoid cystic carcinomas.
  • In tissue specimens, none of the 25 histologically normal oral mucosal specimens had detectable ICAM-5 level, whereas 16 (64%) of the 25 matched primary squamous carcinomas showed expression.
  • Carcinoma specimens high ICAM-5 expression had a high incidence of perineural invasion.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Head and Neck Neoplasms / metabolism. Membrane Glycoproteins / metabolism. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Adhesion Molecules. Cell Transformation, Neoplastic / metabolism. Chromones / pharmacology. Enzyme Inhibitors / pharmacology. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Morpholines / pharmacology. Mouth Neoplasms / metabolism. Mouth Neoplasms / pathology. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis / methods. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. RNA, Messenger / genetics. RNA, Neoplasm / genetics. RNA, Small Interfering / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975520.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / ICAM5 protein, human; 0 / Membrane Glycoproteins; 0 / Morpholines; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down






Advertisement